Dermatology Pipeline

In December 2008, Valeant acquired Dow Pharmaceutical Sciences, Inc., a specialty pharmaceutical company that added four new proprietary compounds to its dermatology product pipeline ranging from treatments for rosacea and oral acne to topical anti-fungals.